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CHAPTER 1 
INTRODUCTION AND OUTLINE 
OF THE STUDY 
TON J .M.CLEOPHAS, JAN F . M . FENNIS, 
ALBERT VAN 't LAAR 
Department of Medicine, University of Nijmegen, 
The Netherlands 

CHAPTER 1 
I N T R O D U C T I O N A N D O U T L I N E 
OF THE S T U D Y 
1.1. DEFINITION AND HISTORY 
In 1862 Maurice Raynaud in Paris wrote his thesis entitled: 
"De l'asphyxie locale et de la gangrène symétrique des extré-
mités" 11]. Sir Thomas Barlow (London) in 1883 introduced 
the term Raynaud's disease [2]. In 1901 Hutchinson proposed 
the term Raynaud's phenomenon, suspicious that different con-
ditions might contribute to the development of the syndrome [3). 
In 1932 Allen and Brown [41 proposed criteria for Raynaud's 
disease that are used until today: (1) absence of any disease or 
abnormality to which paroxysmal digital ischemia might be 
secondary; (2) well demarcated digital pallor or cyanosis occurring 
in intermittent attacks, induced by cold or emotion; (3) sym-
metrical or bilateral involvement of the digits; (4) gangrene if 
present usually limited to small areas of skin. Raynaud's phenome-
non can be diagnosed by discovering an underlying condition that 
is likely to have caused the attacks. Instead of Raynaud's disease 
and Raynaud's phenomenon respectively, the terms primary and 
secondary Raynaud's syndrome are applied. The underlying 
condition in secondary Raynaud's syndrome is a connective 
tissue disease e.g. systemic sclerosis, reumatoid arthritis, lupus 
erythematosus (up to 50% of all patients presenting with Ray-
naud's syndrome in a prospective study of Porter et al. [5]. 
Cold extremities or a syndrome similar to Raynaud's syndrome 
may occur with occlusive arterial disease [6, 7, 8], vibration 
3 
4 Chapter î 
syndrome [9], with some drugs e.g. ergot alkaloids [10], beta-
blockers [11, 31] with blood dyscrasias [12, 13], neurological 
lesions [13, 14]. However, in the present study these conditions 
have been excluded. 
1.2. TREATMENT OF RAYNAUD'S SYNDROME 
A wide variety of therapies has been used in the treatment of 
Raynaud's syndrome, most of them with disappointing clinical 
results [15, 16, 17]. Some of them have, therefore, been 
abandoned. E.g. surgical sympathectomy [18], commonly per-
formed for severe Raynaud's syndrome for many years, nowadays 
is dissuaded because of poor results and recurrence of symptoms 
[5]. The efficacy of intra-arterial injections of reserpine is in 
serious doubt since the observations of Siegel [19] who found 
no difference in effect of intra-arterially administered saline and 
reserpine in scleroderma with severe Raynaud's phenomenon. 
The so-called directly smooth muscle relaxing agents, e.g. nitro-
glycerine, papaverine, niacine, cyclandelate, though commercially 
promoted, apparently are not of any clinical value [16, 17, 20]. 
Although recently some newer drugs have been tried e.g. prosta-
glandin Ei, SQ 14225 (Captopril), nifedipine, reports on them 
were either without objective evidence of improvement or poorly 
documented [21, 22, 23]. In a small series a benificial effect of 
plasmapheresis has been demonstrated [24]. This effect has been 
considered a consequence of removal of circulating immune com-
plexes [25]. We also found clinical benefit of plasmapheresis in 
3 Raynaud-patients with presumably circulating immune com-
plexes (a positive C l q binding test, decreased levels of C3, C4, 
factor B). However, we believe that more data are needed both 
to determine the place of this rather laborious therapy and to 
get a better insight into the relationship between Raynaud's 
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syndrome and auto-immune disease. Several reports came out 
on the effects of methyldopa, alpha-blockers and beta-agonists 
[20, 26, 27, 28, 29, 30], whereas beta-blockers were reported to 
induce Raynaud's phenomenon in subjects without a history of 
cold sensitivity [11, 31]. These findings were the principal reason 
for the present thesis and will be discussed next. 
1.3. A L P H A - B L O C K A D E IN R A Y N A U D ' S S Y N D R O M E 
The etiology of Raynaud's syndrome is unknown. However, 
ever since the description of Raynaud in 1862 the sympathetic 
nervous system has been judged to be of importance in its patho-
genesis. Raynaud's own philosophy about pathogenesis was: 
"a neurosis characterized by enormous exaggeration of the excito-
motor energy of the grey parts of the spinal cord which control 
vasomotor innervation" [1]. In 1948 Ahlquist [32] has described 
his theory of adrenergic receptors — skin vessels appeared to 
contain predominantly alpha-receptors — and it was in the same 
time that the first alpha-adrenergic receptor blocking agent phe-
noxybenzamine was developed [33]. Since that time in patients 
with Raynaud's syndrome alpha-adrenergic receptor blockers 
sometimes have been found to give alleviation of symptoms 
[29, 34—37], improvement of finger flow [26], and of fìnger skin 
temperature [29, 34, 36]. However, all these studies were neither 
double-blind nor placebo controlled. Therefore, some doubt 
remains as to the real efficacy of these drugs. 
1.4. BETA-STIMULATION IN RAYNAUD'S SYNDROME 
Induction of peripheral coldness and a syndrome resembling 
Raynaud's phenomenon is a well-known adverse effect of beta-
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blockers [11, 31]. This gave cause for studies on the effects 
of the beta-agonist terbutaline in Raynaud's phenomenon [27, 
30]. Benifkial effects could be demonstrated. However, as these 
studies were not double-blind nor placebo controlled, doubt 
remains also as to the efficacy of beta-stimulation. Furthermore, 
no comparative studies of alpha-bloc kers and beta-stimulators 
in this condition have been published. 
1.5. COMBINED ALPHA-AND BETA-BLOCKADE IN 
RAYNAUD'S SYNDROME 
Alpha-blockers have not been widely used, probably because 
of serious adverse effects that are likely to appear, namely tachy-
cardia [38], postural and exercise-induced hypotension [39] and 
fluid retention [40], probably in part a consequence of stimulation 
of the renin-aldosterone system. Tachycardia and increased renin 
activity have been ascribed to beta-receptor stimulation [38]. 
In hypertensive patients postural hypotension did not appear 
on the combination of alpha- and beta-blocker [41, 42] . So, 
theoretically alpha-blocker side effects may be counteracted 
by concomitant beta-blockade. However, beta-blockers can induce 
a syndrome resembling Raynaud's syndrome [11, 31], and may 
therefore reduce the therapeutic effect of the alpha-blocker. 
Besides, beta-blockers can reduce blood pressure in hypertensive 
patients and may therefore enhance the hypotensive effect of 
alpha-blockers in patients with Raynaud's syndrome, rather than 
prevent orthostatic or exercise induced hypotension. 
These problems made it worthwhile to investigate this com-
bined alpha- plus beta-blocker therapy in patients with Raynaud's 
syndrome. 
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1.6. THERAPEUTIC EFFICACY OF ADRENERGIC 
RECEPTOR BLOCKING DRUGS IN PRIMARY AND IN 
SECONDARY R A Y N A U D ' S SYNDROME 
Patients with Raynaud's phenomenon with associated auto-
immune disease are classified as having secondary Raynaud's 
syndrome, and those without this association as primary. Primary 
Raynaud's syndrome is considered as a purely vasospastic disease, 
the secondary syndrome as both a vasospastic and obstructive 
disease [5]. Therefore, one might expect less therapeutic efficacy 
of adrenergic receptor blockers in secondary Raynaud's syndrome. 
However, this point has never been studied. 
1.7. OUTLINE OF THE STUDY 
In our study we tried to find an answer to the following questions: 
(1) Is alpha-blockade benificial in Raynaud's syndrome? 
(2) Is beta-stimulation benificial in Raynaud's syndrome? 
(3) Does beta-blockade prevent alpha-blocker side effects? 
(4) Does beta-blockade reduce the eventual benificial effect 
of alpha-blockade ? 
(5) Is there a difference in susceptibility to alpha-blockade 
between primary and secondary Raynaud's syndrome? 
Before therapeutic trials on patients with Raynaud's syndrome 
could be performed, it was necessary to study the literature on 
the measurement of finger blood flow (Chapter 2). Subsequently, 
we set up a standardised finger cooling test and studied the repro-
ducibility of the recovery of finger temperature after cooling 
in normal subjects. In addition, the influence of air temperature 
and cigarette smoking on the result of the test was investigated 
(Chapter 3). 
The first four questions were investigated in a double-blind 
8 Chapter 1 
placebo controlled pilot study (Chapter 4). In 12 patients with 
Raynaud's syndrome we studied the effects of a single dose of 
the above-mentioned drugs and combinations of them. As a 
measure of the therapeutic effect we used finger skin temperature 
and its recovery after a standardised cooling of the fingers. Blood 
pressure and heart rate served as the principal variables to judge 
the occurrence of side-effects. 
On the base of the results of this pilot study we selected the 
most promising drug and drug-combination. These were evaluated 
in a longer lasting double-blind placebo-controlled study (cross-
over design) in 32 patients (Chapter 5). This number of patients 
permitted abo the answering of the question about the eventual 
difference between primary and secondary Raynaud's syndrome 
in susceptibility to treatment (Chapter 6). Again, the parameter 
for efficacy of treatment was fìnger skin temperature, and its 
recovery after a standardized cooling. Furthermore, a question-
naire about clinical symptoms and side effects was used and the 
effect of treatment on blood pressure, heart rate and body weight 
was studied. 
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CHAPTER 2 
THE MEASUREMENT OF BLOOD FLOW 
IN THE FINGERS 
2.1. FINGER SKIN TEMPERATURE AS A MEASURE 
OF BLOOD FLOW 
Burton 1 designed a thermal circulation index derived from 
skin temperature. It is based on a physical analysis of the flow 
of heat from the interior of the body, where it is generated, 
to the surface. There are a physiological gradient of temper­
ature, given by the difference between rectal and skin temper­
ature and a physical gradient between skin and air temperature. 
The flow of heat down each of these gradients is governed by 
Newton's law of diffusion: 
Heat flow = Q (Temperature
 r e c t u m - Temperature s k i n ). 
Ci, the so-called effective thermal conductivity, expresses the 
"ease" of heat flow and is mainly determined by skin blood flow. 
For the physical gradient the similar equation is: 
Heat flow = Сз (Temperature
sk in — Temperature ^ ). 
Since the flow of heat arriving at the skin, is equal to that leaving 
it, we have the identity: 
Ci (Temperature
r e c t u m — Temperature „ ) = 
o r
. = C2 (Temperature s k i n - Temperature^ ) 
Ci Temperature skin — Temperature . 
C2 Temperature r e c t u m — Temperature skin 
15 
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Ci/Cj is called the thermal circulation index which can be used 
as a measure for skin flow (Οχ is variable, C2 — the physical 
conductivity — is usually constant). 
So, theoretically, finger skin temperature is almost exclusively 
determined by total finger blood flow. Figure 1 [2] shows the 
experimentally established relationship between flow and skin 
temperature which very well answers the theoretical relationship. 
The interpretation of skin temperature in terms of flow is 
not valid if muscles with relatively high blood flow are directly 
adjacent to the skin, but in the fingers these are few and un­
important. The equation also does not provide for the delay of 
temperature rise if flow is not in steady state. However, a rapid 
rise of finger temperature with a time-lag of only 20 seconds 
can be expected after an increase of blood flow [1]. The equation, 
furthermore, neglects sweating and evaporation, but these are 
low in resting subjects in a not draughty room. Despite these 
restrictions we conclude that it seems justified to use finger 
skin temperature for the estimation of finger blood flow. 
2.2. VENOUS OCCLUSION PLETHYSMOGRAPHY 
Venous occlusion plethysmography [3, 4] is based on the follow­
ing principle: a collecting pressure, e.g. at 70 mm Hg, is applied 
by a cuff at the root of the finger, that is, if finger flow is the 
object of research. Different types of Plethysmographs (water-
filled, air-filled, strain-gauge) can be used to register the accumu­
lating of blood in the finger with each pulse wave after inflation 
of the cuff. From a tangent drawn to at least three pulse waves, 
flow can be calculated. The hands of the sitting subject should 
be kept on a desk with a surface not lower than the subject's 
heart. Similarly the method can be used to measure flow in arms 
or hands, and, in fact, this has been done widely for many years. 
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Fig. 1. Empirical relationship between blood flow and skin temperature 
in finger and hand of normal subjects. The mean curve has been calculated 
from 90 measurements in 20 normal subjects (for the finger). Flow measure­
ment was performed by venous occlusion plethysmography. (Drawn from 
Aschoff: 1958, Klin. Wschr. 36, 193.) 
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Until now, it is the only non-invasive quantitative method to 
measure peripheral blood flow. However, for the fingers it can 
only be used with important restrictions. 
One group [7] reported that this method could not always 
be applied. Whereas at a skin temperature above 24 0 C a tangent 
to at least three pulse waves after inflation of the cuff generally 
could be drawn, this was often impossible at lower temperatures 
[7]. They used a water-filled Plethysmograph. Using strain-gauge 
plethysmography according to Brakkee and Vendrik [8J in a 
preliminary study, our findings were similar. So, in our hands, 
venous occlusion plethysmography appeared to be an unsuitable 
method to measure flow in some patients with low skin temper-
ature. 
2 .3 . SOME VARIABLES INFLUENCING BLOOD FLOW 
IN THE FINGERS 
Air temperature 
Earlier studies [2] have indicated that normal subjects at rest in 
light clothing have a skin circulation at a room temperature of 
24 0 C , resulting in a skin temperature of about 30 0C. However, 
at a room temperature of 20 0 C skin flow is very small, resulting 
in a decrease of skin temperature to environmental level. Figure 2 
[2] shows the experimentally established relationship between 
air temperature and blood flow and skin temperature of the hand. 
It should be stressed that the values are steady state data, reached 
after a period of equilibration at a constant air temperature, 
at rest and with light clothing. Apparently, experiments on fìnger 
flow as done in our studies, should be performed at air tempera-
tures higher than 20 "C, and they should not start before suffi-
cient equilibration has taken place. Of course, air temperature 
should be kept constant throughout the whole experimental 
The Measurement of Blood Flow in the Fingers 19 
skin 
tennperature(0C) 
36-1 hands 
3 2 -
2 8 -
2 4 -
2 0 -
16 
ml/IOOmUmin 
г 20 
skin tem­
perature 
blood 
flow 
-16 
-12 
- 8 
- 4 
16 20 24 2 8 32 
room temperature ( 0 C) 
Fig. 2. Empirical relationship between air temperature and blood flow and 
skin temperature of the hand. (Drawn from data of Aschoff: 1958, Klin. 
Wschr. 36, 193.) 
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Fig. 3. The effects of smoking cigarettes on finger skin temperature. (Drawn 
from data of Maddock, W. G. and Collier, F. Α.: 1932, Proc. Soc. Exp. Biol. 
Med. Sci. 52, 285-290.) 
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session. In Chapter 3 we report some experiments in normal 
subjects that give further evidence of the importance of the 
influence of air temperature. 
Smoking Habits 
Smoking causes cutaneous vasoconstriction, resulting in a sharp 
drop of fìnger skin temperature (Figure 3) [9]. This effect general-
ly has been considered to be of short duration (10 to 20 min), 
which is in agreement with the rather short plasma half life of 
nicotine [10, 11]. This implies that the testing of the effects 
of drugs on finger flow should not be performed immediately 
after smoking a cigarette. In Chapter 3 some experiments are 
presented indicating that the influence of smoking on peripheral 
circulation in fact lasts much longer than 20 min, actually even 
24 hours. Therefore, only non-smoking subjects have been ad-
mitted to our experiments on the efficacy of drugs in Raynaud's 
syndrome. 
2.4. COLD WATER CHALLENGE 
In our study we investigated the influence of several drugs on 
Raynaud's syndrome. One of the parameters for improvement of 
finger blood flow was the finger temperature, measured after 
some time of equilibration at an environmental temperature of 
24 "C. As most important parameter, however, we used the 
recovery of finger skin temperature after a standardized cold water 
challenge. Such a standardized cold exposure has been used by 
many authors in the study of Raynaud's syndrome [12—19]. 
The purpose of the cold exposure is to evoke a digital vasocon-
striction, which serves as a model for a Raynaud attack. Indeed, it 
generally has been found that Raynaud-patients have a more 
severe [20] or longer lasting [14] vasoconstriction than normal 
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subjects. Shortening of the duration of this cold-evoked vaso-
constriction is considered as a proof of the benifkial effect of a 
drug in Raynaud's syndrome [12—18]. As a cold exposure test we 
used a modification of the method of Hansteen 115], that will be 
extensively described in the following chapters. Also in this test 
fìnger skin temperature is used as an index of finger blood flow: 
a rise of finger skin temperature is considered as evidence of 
an increase in blood flow. 
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CHAPTER 3 
FINGER TEMPERATURE AFTER A FINGER 
COOLING TEST. 
INFLUENCE OF AIR TEMPERATURE AND 
CIGARETTE SMOKING 
Abstract. Skin temperature of one fìnger was measured before and after 
immersion of the gloved fingers of both hands in water at 16 С for 5 min; 
room temperature, T
a
 =24 C. In T
a
 = 24 C, twenty-three of twenty-five 
normal non-smokers (92%) had a finger rewarming to above 24 С in 12 min 
after cold immersion; in Г,, = 20 С, only one of twelve (8%). Among twelve 
habitual smokers only four (33%) rewarmed above 24 С (Г,, = 24 С) follow­
ing a 1-hr abstinence from smoking, but eight (67%) did so after a 24-hr 
abstinence. . Only two of these eight, however, did so in a retest 10 min after 
smoking a cigarette. The smokers were not tested at T
a
=20 C. Conclusion: 
Air temperature and cigarette smoking are important determinants of finger 
rewarming following a finger cooling test. 
Finger skin temperature, air temperature, cigarette smoking, Raynaud's 
phenomenon. 
FINGER SKIN TEMPERATURE is closely related to total digital 
blood flow [2,4, 8] . Indeed, in the study of Raynaud's syndrome, 
the recovery of finger skin temperature after finger cooling has 
widely been used as a parameter for the disappearing of a cold-
induced vasoconstriction [5, 7, 14, 20, 22, 25, 26, 27]. However, 
there is a lack of data on the intra-individual reproducibility of 
this kind of testing, even in normal subjects. Moreover, in equili­
brated normal subjects finger skin temperature and total finger 
blood flow appear to be dependent on variables such as environ­
mental temperature [9, 10] and smoking habits [1 , 11, 16, 17, 
23]. However, it is unknown to what extent the recovery of fìnger 
skin temperature after finger cooling migt be influenced by these 
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variables. Therefore, these problems were studied in normal 
subjects, both non-smokers and habitual smokers. 
3.1. METHODS 
Twenty-five non-smoking subjects and twelve habitual smokers 
(at least 15 cigarettes a day), volunteered in the study. In the 
first group there were thirteen women and twelve men, 20—42 
years of age. In the second group there were nine women and 
three men, 24—55 years of age. AH women were premenopausal, 
but in uncontrolled phases of the menstrual cycle. 
A finger cooling test was performed according to the method 
of Hansteen [14] . The seated subject equilibrated for 15 min 
at a room temperature, 7^ = 2 4 1 0 . 5 0 C , humidity 40%, after 
which the temperature on the distal, volar surface of the right 
middle finger was measured with an applied thermistor probe 
(Ellab Instruments, Copenhagen). Then, the subject's hands 
were placed in plastic gloves — individually fitted to avoid both 
compression and air entrapment —, and immersed in water of 
16 "C to just beyond the metacarpophalangeal joints during 
5 min. The subject gently moved his immersed hands to intensify 
the cooling [13] . After taking off the gloves, skin temperature 
was measured as described each minute for 12 minutes. Skin 
temperature after 12 min was used as a measure for ultimate 
recovery, because at this moment in most healthy subjects a 
complete recovery has been reached [20] . Skin temperatures 
after 12 min higher than 24 ° С were considered to be good re­
coveries and lower values poor recoveries. Sweating of the fingers 
was not observed. 
Reproducibility of the test was studied in the twenty-five 
non-smoking volunteers, by performing the test 2 times in each 
of them, intervals ranging from half an hour to a week (median: 
5 days). 
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Influence of air temperature was studied one week later in 
twelve of the above subjects who showed a good recovery on 
both former occasions. In them, the test was performed one 
more time at Γ
α
 = 2 4 ± 0 . 5 " С (humidity 40%) and finally 24 
hours later at T
a
 = 20 ± 0.5 eC (humidity 4 0 - 5 0 % ) . 
In twelve habitual smokers the influence of cigarette smoking 
was studied in 3 sessions, each of them at T
a
 = 24 ± 0 . 5 "C, hu­
midity 40%. The first and second session took place with an 
interval of 1 week. The subjects had refrained from smoking 
during at least 1 hour before the experiments started. At the 
third session, which took place 1 day after the second they had 
not smoked for 24 hours. Each session consisted of at least one 
fìnger cooling test. In cases of good recovery this test was im-
mediately followed by the smoking of a cigarette. At a rate of 
only 1 inhalation per min smoking was performed in order to avoid 
inhalation-induced vasoconstriction [20] . After finishing this 
cigarette fìnger temperature was measured, and 10 min later a 
second finger cooling test was performed. 
For statistical analysis we used Wilcoxon's test for paired data. 
3.2. RESULTS 
The intra-individual reproducibility of the finger cooling test 
at Ta = 24 0 C , as observed in the twenty-five non-smoking sub-
jects, is illustrated in Figures 1 and 2. In twenty-three subjects 
recovery was good on both occasions. Reproducibility in this 
well-recovering group could be characterized by an overall dupli-
cate standard deviation of 0.9 0C at 12 min after cooling; in the 
male this duplicate standard deviation was 0.8, in the female 
1.2 0 C. Two subjects, both young females, repeatedly showed 
a poor recovery. 
The influence of Ta on the result of the fìnger cooling test 
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Fig. 1. Mean values (± SEM) of skin temperature curves in 23 normal 
subjects (first test). All subjects were examined a second time; duplicate 
standard deviations are given at the times —5, 0, and 12 minutes. Results 
of 2 poorly recovering normal subjects are given separately: first subject's 
curves with dotted lines, second subject's curves with thin continuous lines 
(Г<1 = 2 4 ± 0 . 5 о С ) . 
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Fig. 2. Individual skin temperatures 12 minutes after cold exposure in 
the first and in the second test (normal subjects, Ta = 24± 0.5 C). 
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Fig. 3. Skin temperature curves in 12 normal subjects tested at 
Га = 2 4 ± 0 . 5 "С (continuous lines) and 24 hours later at Ί
α
= 20±0.5 "С 
(dotted lines). 
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Fig. 4. Individual skin temperature 12 minutes after cold exposure in 
smokers tested after at least 1 hour abstinence from smoking and 10 minutes 
after a cigarette (left); on the right side, the same procedure 1 week later. 
Closed circles represent subjects, who were already recovering poorly in 
the first test. On both occasions these were the same subjects {T
a
 = 24 "C). 
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Fig. 5. Individual skin temperature 12 minutes after cold exposure in 
smokers tested after 24 hours abstinence from smoking. The well recovering 
subjects were retested the same morning 10 minutes after finishing a cigarette. 
Closed circles represent subjects, who were already recovering poorly in the 
first test (Ta = 24 ± 0.5 0C). 
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Fig. 6. Skin temperature curves in 8 smokers tested after 24 hours absti­
nence from smoking (continuous lines] and after finishing a cigarette (dotted 
lines). ( ^ = 24 ±0.5 0C). 
36 Chapter 3 
36-1 n = 8 
3 2 -
2 8 -
2 A 
2 0 
• N S . 
ι ρ < 0.05-
cigarette 
- τ -
0 10 
1 — 
20 
t ime (min ) 
Fig. 7. Skin temperature at Γβ=24±0.5 С, before and after smoking 
a cigarette in 8 habitual smokers who had refrained from smoking during 
the preceding 24 hours. (N.S. = not significant). 
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is demonstrated in Figure 3. Recovery was poor at T
a
 = 20 0 C 
in eleven of twelve subjects who on 3 previous occasions at 
T
a
 = 24 "C, had shown a good recovery. Also immediately after 
cooling, at T
a
 = 20 0 C , skin temperatures were significantly lower 
than at Τα = 24 " С (medians 17.0 and 20.2 "С, respectively, 
ρ < 0.05). Immediately before cooling, at T
a
 = 20 0 C and at 
T
a
 = 24 0 C skin temperatures were not significantly different 
(medians of 28.4 and 30.0 0 C , respectively). 
The results of the experiments on smokers are demonstrated 
in Figures 4 and 5. After abstinence from smoking of at least 
1 hour, eight of twelve smokers showed a poor recovery at both 
the first and second sessions. At the same sessions the other 
four smokers, initially showing a good recovery, displayed a poor 
recovery 10 min after finishing a cigarette. At the third session, 
after 24 hours of abstinence from smoking, recovery was good 
in eight of twelve smokers. Repeating the test in these eight 
smokers 10 min after finishing a cigarette, results were poor in 
six. Detailed results in these eight smokers at the third session 
are shown in Figure 6. The smoking of a cigarette did not sig­
nificantly influence skin temperatures before or immediately after 
cooling: median pre-cooling and after-cooling values were 28.3 
and 19.9 e C before smoking, and 29.6 and 19.9 0 C after smoking. 
In the smokers skin temperature always dropped temporarily 
during smoking. This is shown in Figure 7 for the eight smokers 
who, after 24 hours abstinence, had a good recovery. 
3.3. DISCUSSION 
The recovery of finger skin temperature after cold exposure in 
normal subjects apparently is a well-reproducible phenomenon. 
In a group of twenty-five normal volunteers twenty-three subjects 
repeatedly exhibited a good recovery. Small duplicate standard 
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deviations indicate a good intra-individual reproducibility of 
this phenomenon. 
Only two of the above twenty-five subjects repeatedly showed 
a poor recovery. Also Porter et al. [20] found a poor recovery 
to be rather rare: in one out of thirty normal subjects. Both 
our poor recovering subjects were young females. This could be 
in agreement with the observation of a general tendency in young 
women to prolonged digital vasospasm on cold exposure [ 3 ] . 
However, an early stage Raynaud's syndrome cannot be excluded 
in these two subjects. Although they never had Raynaud-like 
complaints, both had a parent suffering from Raynaud's syn-
drome, which is known to be sometimes familial [12] . 
There remains some possibility, that in the female the intra-
individual reproducibility of this kind of testing is influenced 
by the phase of the menstrual cycle. We did not record this 
phase in our subjects, so pertinent conclusions cannot be drawn. 
However, the small difference in duplicate standard deviations 
between the males and females does not suggest an important 
influence. 
As can be seen in e.g. Figure 3 a standard cold water challenge 
caused inter-individually different degrees of cooling, indicating 
different degrees of vasoconstriction. The good intra-individual 
reproducibility indicates that not inconsistent cooling but an 
inter-individually different cold sensibility is responsible for 
this effect. 
Environmental temperature appears to have an important 
influence on the recovery of fìnger skin temperature after cold 
exposure. At Ta = 20 "C the cooling resulted in a lower finger 
temperature, indicating a higher degree of vasoconstriction. We 
can only speculate about the cause of the subsequent slow and 
poor recovery. It could be this higher degree of vasoconstriction 
reached during immersion or the low environmental temperature, 
during the recovery period, or the combination of both factors. 
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Anyway, as a practical point in studying the influence of drugs 
in Raynaud's syndrome, one should conduct this kind of experi-
ments at environmental temperatures of at least 24 0C, otherwise 
it cannot be excluded that results are biased by some grade of 
physiological vasospasm. Our results are consistent with the 
preliminary data of Chucker [ 6 ] , who thermographically ob-
served incomplete rewarming of the fingers in seven normal 
subjects at 21 0C, whereas at 24 "C rewarming was good in five 
out of seven subjects. 
Cigarette smoking impaired the recovery of finger skin temper-
ature after cold exposure considerably. However it did not 
influence the degree of cooling. So nicotine does not seem to 
influence the degree of cold-induced vasoconstriction, but only 
the rate of vasodilation. 
Cigarette smoking causes cutaneous vasoconstriction, resulting 
in a transient fall in skin temperature [11, 17, 23, and Figure 7 ] . 
The short duration of this effect is in agreement with the rather 
short plasma half life of nicotine [15, 2 4 ] . However, in our 
experiments, 10 minutes after finishing a cigarette, at the time 
that the acute effects of nicotine on digital skin temperature 
seemed to have passed, recovery of skin temperature after cold 
exposure was still abnormal. One hour after smoking and even 
24 hours after smoking, recovery still was poor in several subjects. 
The effect of nicotine on the peripheral circulation apparently 
lasts much longer than is generally assumed. This result supports 
the "stop smoking" advise physicians use to give to their patients 
with peripheral vascular diseases. Also it gives a better under-
standing of the delay of wound healing caused by cigarette 
smoking [18]or by nicotine administration [19] . If a skin temper-
ature recovery test is applied in the study of Raynaud's syndrome, 
smoking habits should be accounted for, which till now was not 
the case in most studies [e.g. 14, 20, 21 , 22, 25, 2 7 ] . 
Summarizing we conclude that environmental temperature 
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and smoking are important determinants of skin temperature 
recovery after cold exposure, if these determinants are controlled, 
a standard cold water challenge gives a reproducible effect on 
fìnger skin temperature. 
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C H A P T E R 4 
ALPHA- AND BETA-BLOCKADE AND 
BETA-STIMULATION IN RAYNAUD'S SYNDROME 
A Double-Blind, Placebo Controlled, Single Dose Study 
Abstract. Treatment with an alpha-Ыоскег has been considered benificial 
in Raynaud's phenomenon, whereas a beta-blocker might aggravate the 
condition. We examined in a double-blind fashion and placebo controlled 
the effects of a single dose of several of these kinds of drugs and combi­
nations of them on the recovery of fìnger skin temperature 12 min after 
fìnger cooling (5 min waterbath for both hands) in twelve patients with 
Raynaud's syndrome. A favourable effect was established on phenoxy-
benzamine 20 mg as compared to placebo. A significant but rather small 
effect on orciprenaline 10 mg. The beta-agonists prenalterol (10 mg) and 
terbutaline (5 mg) did not influence the recovery of finger skin temperature. 
The benificial effect of phenoxybenzamine 20 mg was not influenced by 
the addition of beta-agonists (prenalterol 10 mg or terbutaline 5 mg) or a 
beta-blocker (propranolol 40 mg). 
The beta-agonists terbutaline and orciprenaline caused a fall in diastolic 
pressure and an increase in heart rate. These effects presumably were con-
nected with one collaps and three near-collapses. On alpha- and beta-blocker 
(phenoxybenzamine and propranolol) a decrease in systolic pressure appeared, 
whereas diastolic pressure did not significantly differ from the placebo value. 
While physical exercise is considered to exacerbate the hypotensive effect 
of alpha-blockers, a fall in blood pressure during physical exercise could 
not be established in our experiments after the addition of propranolol to 
the alpha-blocker phenoxybenzamine. Our results suggest that an alpha-
blocker might be the drug of choice in Raynaud's syndrome, whereas the 
addition of a beta-blocker might have some advantages. 
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In patients with Raynaud's phenomenon adrenergic alpha-blockers 
have been said to give relief of symptoms [11 , 15, 3 1 , 37, 40], 
improvement of digital blood flow [4], and digital skin temper-
ature [11, 3 1 , 40]. These benificial effects have been ascribed to 
a beta-agonist as well [36, 41] . However, all these studies were 
neither double-blind nor placebo-controlled. Therefore, some 
doubt remains as to the efficacy of these drugs. Furthermore, 
no comparative study of the two therapies has been published. 
With alpha-blockers serious adverse effects are likely to occur, 
namely tachycardia [19], increased plasma renin concentration 
[19], postural and exercise-induced hypotension [29], and fluid 
retention [3]. The first two have been ascribed to beta-receptor 
stimulation [19], whereas the third one in hypertensive patients 
did not appear on the combination of alpha- and beta-blocker 
[21 ,25] . 
Therefore, it seemed worthwhile to investigate this combined 
alpha- and beta-blocker administration in patients with Raynaud's 
syndrome as well. 
In this chapter we report a double-blind study of the effects 
of a single dose of several of the above-mentioned types of drugs 
and combinations of them in patients with Raynaud's syndrome. 
The following compounds were chosen: the alpha-blocking agent 
phenoxybenzamine, the non-selective beta-agonist orciprenaline, 
the betai-selective stimulator prenalterol, the beta2 -selective 
stimulator terbutaline, and the non-selective beta-blocker 
propranolol. Their influence on the recovery of finger skin temper-
ature after a finger cooling test was investigated. Besides, attention 
was paid to the effects of the different compounds on blood 
pressure and heart rate. 
Alpha- and Beta-blockade and Beta-Stimulation 47 
4.1. SUBJECTS AND METHODS 
Twelve patients with Raynaud's syndrome, who had given their 
informed consent, participated in the study. Each patient had 
been examined at our outpatient clinic. Diagnoses had been 
established by the conventional criteria [9]. Raynaud's disease 
had been diagnosed in ten patients, Raynaud's syndrome in two 
(one with reumatoid arthritis, one with systemic sclerosis). The 
duration of the syndrome at the time of entry into the study 
varied from 2 to 20 years (average 5.3 years). There were seven 
men and five women. Patients were told to stop drug therapies 
concerning Raynaud's syndrome 14 days before entering the 
study. AH patients had stopped smoking at least several months 
ago or had never smoked before. The average age was 39.3 years 
(30—63 years). 
A fìnger cooling test was performed according to the method 
of Hansteen [17]. The seated patient equilibrated for 15 min at a 
room temperature of 24 ± 0.5 "С, in order to avoid a physiological 
vasoconstriction [6], and a humidity of 40%, after which the 
temperature on the distal, volar surface of the right middle finger 
was measured with an applied thermistor probe (Ellab Instruments, 
Copenhagen). Then, the subjects's hands were placed in plastic 
gloves — individually fitted to avoid both compression and air 
entrapment —, and immersed in water of 16 "С to just beyond 
the metacarpophalangeal joints during 5 min. The patient gently 
moved his immersed hands to intensity the cooling [16]. After 
taking off the gloves, skin temperature was measured as described 
each minute for 12 minutes. Skin temperature after 12 min was 
used as a measure for ultimate recovery, because at this moment 
in most healthy subjects a complete recovery has been reached 
[7, 3 0 ] . 
This test has been performed twice in twenty-five non-smoking 
volunteers. Extensive data are presented ekewhere [7]. It was 
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concluded that twenty-three of these twenty-five subjects repeated-
ly had an approximately complete recovery with good intra-
individual reproducibility, demonstrated by low duplicate standard 
deviations (Figure 1). 
In the twelve patients 9 tests were performed with intervals 
of 4 days. Drugs or placebo were administered orally in a single 
dose after an overnight fast. After 90 minutes the test started. 
In the mean time eating or drinking was not allowed. All patients 
received in random order and in a double-blind fashion the follow-
ing medications: twice a placebo, terbutaline 5 mg, prenalterol 
10 mg, orciprenaline 10 mg, phenoxybenzamine 20 mg, two 
combinations of drugs namely phenoxybenzamine 20 mg with 
prenalterol 10 mg, and phenoxybenzamine 20 mg with terbu-
taline 5 mg. 
Registrations of blood pressure (arteriosonde 1217) and heart 
rate (electrocardiograph) were made every 3 minutes during 
the test. In the results, however, only the values immediately 
before finger cooling will be given. 
At the end of the trial the test was performed one more time 
in our twelve patients single-blindly after phenoxybenzamine 
20 mg with propranolol 40 mg. This time, 12 minutes after finger 
cooling, after the last measurement of skin temperature, an 
exercise-test was performed. This was done in a sitting position 
on a bicycle ergometer (Lode) at a pedalling rate of about 50 
cycles per minute, the amount of load chosen was 40 watts, for 
5 minutes. Immediately after this test in the same position blood 
pressure (arteriosonde 1217) and heart rate (electrocardiograph) 
were registered. 
For statistical analysis we used Wilcoxon's signed rank test 
for paired data to compare effects of placebo and different drugs. 
Wilcoxon's rank sum test was used to compare skin temperatures 
in normal subjects with the values in our patients, while on 
placebo. 
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Fig. 1. Mean values ± S.D. of finger skin temperature curves in twenty-
three normal subjects (upper curve) and in twelve patients with Raynaud's 
syndrome after the administration of a placebo tablet (lower curve). All 
persons were examined a second time; duplicate standard deviations are 
given in the figure at the times —5, 0, and 12 min. 
TABLE 1 
Finger skin temperatures in patients with Raynaud's syndrome and in normal subjects, at the times —5, 0, 12 min 
after finger cooling (mean ± S.D.). Probabilities relate to the significance of difference between paired data in 
patients compared to the placebo values (Wilcoxon's signed rank test) and difference between unpaired data of 
normal subjects as compared to the placebo values in the patients (Wilcoxon's rank sum test). 
Time after cooling (min) 
Placebo one 
Terbutaline 
Prenalterol 
Orciprenaline 
Phenozybenzamine 
Phenoxybenzamine + Prenalterol 
Phenoxybenzamine + Terbutaline 
Phenoxybenzamine + Propranolol 
Normal subjects 
- 5 
28.9 ± 2.8 "C 
27.2 ± 2.3 
29.9 ± 2.6 
29.4 ± 2.8 
30.8 ± 2.5* 
30.0 ± 2.9* 
29.1 ± 2.5 
29.9 ± 3.4 
32.9 ± 2 . 1 * * 
0 
18.4 ± 0.5 0 C 
18.6 ± 0.4 
18.8 ± 0.5 
19.3 ± 0 . 9 * * 
19.8 ± 1 . 5 * * 
19.8 ± 1.2(*) 
20.0 ± 1 . 3 * * 
20.0 ± 1.3** 
21.4 ± 2.4** 
12 
22.0 ± 1.2 0 C 
22.0 ± 1 . 2 
22.4 ± 1.3 
22.9 ± 1.5* 
26.1 ± 3 . 8 * * 
26.5 ± 3 . 5 * * 
26.5 ± 2.9** 
26.3 ± 4 . 1 * * 
32.7 ± 1.7** 
(*) 0.05 < p < 0.1 
* ρ < 0.05 
** ρ < 0.01 
TABLE 2 
Blood pressure and heart rate (mean ± S.D.) in twelve patients with Raynaud's syndrome after the administration 
of various drugs, measured immediately before finger cooling and in the last instance after exercise. Probabilities 
relate to the significance of difference between paired data as compared to the placebo values. 
Systolic 
blood 
pressure 
Diastolic 
blood 
pressure 
Mean blood 
pressure 
Heart rate 
8. 
I-
to 
¿3 
3 
s 
E* 
δ
-
з 
Placebo one 
Terbutaline 
Prenalterol 
Orciprenaline 
Phenoxybenzamine 
Phenoxybenzamine + Prenalterol 
Phenoxybenzamine + Terbutaline 
Phenoxybenzamine + Propranolol 
Phenoxybenzamine + Propranolol 
+ Exercise 
115 ± 7 mm Hg 81 ± 8 mm Hg 93 ± 6 mm Hg 72 ± 9 
122 ± 11(*) 
122± 10** 
126± 13** 
1 1 6 ± 8 
119± 13 
120 ± 11(*) 
102± 10** 
111± 16* 
68 ± 1 1 * * 
81 ± 6 
73 ± 1 0 * 
7 6 ± 9 ( * ) 
81 ± 7 
78 ± 10 
77 ± 7 
73 ± 9 
8 6 ± 7 ( * ) 
94 ± 6 
91 ± 7 
90 ± 8 
94 ± 7 
92 + 9 
85 ± 7 * 
89 ± 8 * 
95± 15** 
77 ± 10* 
95± 20** 
75 ± 9 
87± 10** 
90± 18** 
62 ± 6 * * 
91± 14** 
0.05 <p< 0.1 
ρ < 0.05 
ρ < 0.01 
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4.2. RESULTS 
In patients with Raynaud's phenomenon the recovery of skin 
temperature was much worse than in normal subjects (Figure 1). 
Also before and immediately after finger cooling skin temperature 
already was significantly lower in the patients (Table 1). The 
results after administration of placebo one and placebo two 
were virtually the same, as is demonstrated by the low duplicate 
standard deviations (Figure 1). In Figure 2 the individual skin 
temperatures 12 minutes after fìnger cooling after administration 
of the various drugs and placebo two are compared with the values 
after placebo one. The beta2-agonist terbutaline and the betaj-
agonist prenalterol do not appear to have any effect on the re-
covery of skin temperature. After orciprenaline seven of twelve 
patients show a better recovery. For the whole group the effect 
is slight, but significant (see Table 1). Also immediately after 
cooling, skin temperature after orciprenaline was significantly 
higher than after placebo. After phenoxybenzamine nine of twelve 
patients have a better recovery of skin temperature. The mean 
effect of this drug was marked. Also before and immediately 
after finger cooling phenoxybenzamine had a significant effect 
on skin temperature. The effect of phenoxybenzamine was not 
significantly augmented by the combination with either prenalterol 
or terbutaline, whereas the addition of propranolol did not signifi-
cantly reduce the effect. 
In Table 2 the effect of the drugs on blood pressure and heart 
rate is shown. After the administration of prenalterol and phenoxy-
benzamine only small differences in blood pressure and heart 
rate from the placebo values occurred. Orciprenaline and terbu-
taline, however, increased heart rate largely, while there was 
a marked decrease in diastolic pressure and an increase in systolic 
pressure. The combination of phenoxybenzamine and propranolol 
induced a decrease in systolic pressure and in heart rate; physical 
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exercise caused no significant further diminution of blood pressure. 
During the exercise test, while on combined alpha- and beta-
blockade, none of the patients complained of dizziness. However, 
while on terbutaline, on standing up one patient collapsed and 
three nearly collapsed. 
4.3. DISCUSSION 
A wide variety of drugs has been used in the treatment of Ray­
naud's phenomenon [10, 12, 18]. The so-called directly smooth 
muscle relaxing agents, e.g. nitroglycerine, papaverine, niacine, 
cyclandelate, though commercially promoted, apparently are 
not of any clinical value [12, 17, 181. Although recently some 
newer drugs have been tried e.g. prostaglandin Εχ, SQ 14225 
(Captopril), nifedipine, reports on them were either without 
objective evidence of improvement or poorly documented [8, 22, 
241. The efficacy of intra-arterial injections of reserpine is in 
serious doubt since the observations of Siegel [33] who found 
no difference in effect of intra-arterially administered saline and 
reserpine in scleroderma with severe Raynaud's phenomenon. 
In the last years several reports came out on the effects of methyl-
dopa, alpha-blockers and beta-agonists on Raynaud's phenomenon 
[4, 17, 36, 39, 40, 41]. However, these studies were not placebo-
controlled nor double-blind and sometimes even without the use 
of objective parameters. Therefore, we studied the effects of some 
of these drugs and some combinations of them by comparing 
their effects on the recovery of skin temperature after finger 
cooling with the effects of a placebo in a double-blind fashion. 
Finger skin temperature is highly related to total finger blood 
flow [2, 5, 14]. Therefore, it seems justified to use the recovery 
of finger skin temperature after fìnger cooling as a parameter for 
the disappearing of a cold-induced vasoconstriction. In our hands 
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the measurements of skin temperature recovery appear to be a 
well reproducible method, which is rather easy to perform. 
A single oral administration of the drug was used, because 
this method permits the study of a rather large number of agents 
in the same patient. Admittedly, in this way no conclusions can 
be drawn as to the ultimate efficacy of the drugs during long-
term treatment. However, the results could be important with 
respect to the selection of a few drugs or combinations of drugs 
for further study. 
Propranolol, a non-selective beta-blocker, previously judged 
to induce Raynaud's phenomenon [27], was taken in our study 
to test whether it could prevent some of the side-effects of alpha-
blockade (postural faintness, exercise-induced hypotension and 
tachycardia), without reducing the therapeutic effect. 
The enhancement of alpha-receptor mediated vasoconstriction 
is considered to be important in the pathogenesis of Raynaud's 
phenomenon [20]. If this is true, alpha-receptor blocking agents 
should be of value. In our study phenoxybenzamine was chosen, 
because it is considered a relatively alphax-selective blocker, with 
low alphaj -blocking activity, and it is the alpha2 -blocking activity 
that has been connected with side-effects characteristically seen 
with alpha-blockers [19]. After one single dose of the drug we 
found a conspicuously better recovery of skin temperature than 
in all other "single drug" tests, whereas side-effects did not occur. 
Induction of peripheral coldness and Raynaud's phenomenon 
is a well-known adverse effect of beta-blockers [27, 42]. This 
finding is hard to understand since skin vessels predominantly 
contain alpha-receptors [1], unless as a phenomenon secondary 
to a fall in cardiac output. Nevertheless it gave cause of studies 
on the effects of the beta-agonist terbutaline in Raynaud's phe-
nomenon [36, 41]. Benifìcial effects could be demonstrated. 
In our experiments only the non-selective agonist orciprenaline 
improved the recovery of skin temperature, whereas the betai-
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agonist prenalterol and the beta2 -agonist terbutaline did not 
have any influence. The beta2 -agonist terbutaline, however, 
caused a considerable fall in blood pressure, and it is known 
that a low level of blood pressure may contribute to the develop-
ment of Raynaud's phenomenon [35]. Although the betai-agonist 
prenalterol did not cause a fall in blood pressure, it could not 
elicit a benificial effect. From these observations one could 
speculate that the benificial effect of the non-selective agonist 
orciprenaline is caused by its beta2-stimulating property and 
consequently that skin vessels in these patients contain, apart 
from their alpha-receptors, a few beta2 -receptors. 
The benificial effect of the alpha-blocker phenoxybenzamine 
was not reduced after the administration of the beta-blocker 
propranolol, even despite a probably unfavourable fall in blood 
pressure. This suggests that the adverse effects peripheral cold-
ness and Raynaud's phenomenon, occurring with beta-blockers in 
50—73% of the cases [27, 42] do not appear in case of additional 
alpha-blockade and consequently, that they are caused by enhanced 
alpha-receptor stimulation and not by blockade of beta-receptors in 
the skin vessels. This is in agreement with the probably only small 
quantity of beta-receptors in the skin vessels as hypothesized above. 
As beta-blockers appear not to diminish the effect of alpha-
blockers in Raynaud-patients, it may be advantageous to use 
them in combination in order to diminish further the side-effects 
of the alpha-blocker. First of all, tachycardia has been ascribed 
to an enhanced beta-receptor stimulation [19, 43] and can be 
effectively countered by beta-blockers [23, 43]. Secondly, 
postural hypotension can be prevented by the addition of a beta-
blocker to the alpha-blocker [23]or did not appear on the combi-
nation of alpha- and beta-blocker [21, 25], although in one acute 
experiment [13] and with high doses [3 , 32] of alpha-blocker 
this could not be confirmed. These high doses may not be needed 
in Raynaud-patients, because of an enhanced alpha-receptor 
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affinity in cooled vessels [38]. Furthermore, some forms of 
postural hypotension have been successfully treated with beta-
blockers with [26] or without intrinsic sympathicomimetic ac-
tivity [28, 34]. In our experiments on combined alpha- and beta-
blockade, despite the same sized fall of blood pressure as on beta2 -
stimulation (terbutaline) (Table 2), none of the patients com-
plained of postural faintness, whereas on beta2 -stimulation four 
of the twelve patients suffered from syncopal reactions. Exercise-
induced hypotension and tachycardia did not appear on alpha-
plus beta-blocker either. 
The value of the present observations is limited as the effects 
were evaluated after a single dose. Nevertheless they suggest that 
an alpha-blocker might be the drug of choice in patients with 
Raynaud's syndrome. It can be speculated that the addition of a 
beta-blocker may be of advantage. Long-term studies are in 
progress to determine further the place of these agents in the 
treatment of Raynaud's syndrome. 
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CHAPTER 5 
TREATMENT OF RAYNAUD'S SYNDROME 
WITH ADRENERGIC ALPHA-BLOCKADE WITH OR 
WITHOUT BETA-BLOCKADE 
Abstract. In a double blind placebo controlled cross-over trial of 24 weeks 
31 patients with Raynaud's syndrome were treated with the alpha-blocker 
phenoxybenzamine (10—20 mg daily) and with the combination of the alpha-
blocker phenoxybenzamine (10—20 mg daily) and the beta-blocker sotalol 
(40—80 mg daily). A favourable effect on recovery of finger temperature 
after fìnger cooling was demonstrated after alpha-blockade as compared to 
the before treatment situation. This favourable effect was not different 
when the group received the combined alpha- and beta-blockade. The blood 
pressure was not influenced by either of the 2 medications. Fluid retention 
appeared with alpha-blockade and was absent with combined alpha- and 
beta-blockade. Decrease of heart rate occurred with alpha- plus beta-blockade 
and was absent with alpha-blockade alone. Clinical symptoms of Raynaud's 
syndrome equally were alleviated by the two medications. Common, and 
equally frequent side effects of the two medications were nasal congestion, 
disturbed ejaculation and potence, dry mouth, exercise-induced, and ortho-
static dizziness. 
We conclude that alpha-blockade is benificial in Raynaud's syndrome 
and that additional beta-blockade counteracts the alpha-blocker side-effect 
fluid retention, reduces the heart rate and thus may prevent alpha-blocker 
induced tachycardia, and that it does not cause hypotension. 
5 .1 . INTRODUCTION 
In a double blind single dose study we previously demonstrated 
a favourable effect of the alpha-adrenoceptor blocker phenoxy-
benzamine in Raynaud's syndrome [ 1]. This finding was consistent 
with earlier reported uncontrolled open studies [2—6]. However, 
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no double-blind studies on chronic alpha-blockade have been 
reported so far in this condition. 
In our previous study [1] , some of the side-effects of alpha-
blockade appeared to be prevented by the addition of a beta-
blocking agent. In particular this pertained to postural dizziness, 
exercise-induced hypotension and tachycardia. These observations 
are in agreement with the recent concept that characteristic 
side-effects of alpha-blockade are due to indirect beta-stimulation 
[7]. Also the effect of a combined treatment with alpha- and beta-
blockade seems to have not been studied in a controlled chronic 
trial in Raynaud's syndrome. 
Therefore, we studied the effects of treatment during 8 weeks 
with the alpha-blocker phenoxybenzamine alone and in com-
bination with the beta-blocker Sotalol in a double-blind cross-
over fashion in patients with this condition. 
5.2. SUBJECTS AND METHODS 
Subjects 
Of all patients eligible for the trial thirty-two gave their informed 
consent. Thirty-one patients completed the trial. One woman 
dropped out in the first week of the trial because of intolerable 
nausea. There were ten men and twenty-one women. The average 
age was 45.2 years (19—70 years). Each patient had been ex-
amined at our outpatient clinic. Diagnoses had been established 
by the conventional criteria [8]. Raynaud's disease had been 
diagnosed in twenty patients, Raynaud's syndrome with con-
nective tissue disease in eleven: five with systemic sclerosis, 
three with reumatoid arthritis, two with CREST* syndrome, one 
with polymyositis. The duration of the syndrome at the time of 
entry into the study varied from 2 to 44 years (average 7.7 years). 
Patients stopped any drug therapy concerning Raynaud's syn-
* CREST = Calcinosis, Raynaud, Esophageal hypomotility, Scleroderma, 
Teleangiectasia. 
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drome 8 weeks before entering the study. All patients were non-
smokers or had stopped smoking since at least 12 months. 
Design of the Study (Figure 1) 
All patients were treated in 3 periods of 8 weeks. In the first 
8 weeks period the alpha-blocker phenoxybenzamine or the 
combination of phenoxybenzamine plus the beta-blocker Sotalol 
were administered in a double blind fashion to two groups of 
16 patients which were formed by block-randomisation. The 
physician was not aware of the method of randomisation. In the 
second 8 weeks period a placebo was administered in a single-
blind way. This was considered as a wash-out period. After this 
wash-out a third 8 weeks period followed in which the alternate 
medication was given. Tablets containing one or both drugs or 
placebo were identical in appearance. The whole study lasted 
from October to April. At the start of the trial and after every 
4 weeks patients were examined at our outpatient clinic. The 
examinations consisted of a procedure described below. Drugs 
were administered in oral doses, which were doubled after 4 
weeks in each period: phenoxybenzamine 5 mg twice daily in the 
first half of the 8 weeks, and 10 mg twice daily in the second 
half; or the same doses of phenoxybenzamine combined with 
Sotalol 20 mg twice daily in the first half of the 8 weeks, and 
40 mg twice daily in the second half. 
Procedure of Examinations 
The patient was seated quiedy in a room of 24 0 С in order to 
avoid a physiological vasoconstriction [91, and a humidity of 
40%. After 15 min the temperature of the volar surface of the 
top of the right third finger was determined by an electronic 
thermometer. Then, the patient's hands were placed in well-
fitting plastic gloves and immersed in water of 16 0 C to just 
beyond the metacarpophalangeal joints during 5 min. The patient 
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gently moved his hands to intensify the cooling. After taking 
of the gloves, finger temperature was measured as before each 
min for 12 min. Finger temperature after 12 min was used as a 
measure for temperature recovery, because in most healthy 
subjects at this moment a complete recovery has been reached 
[10]. 
Registrations of blood pressure (arteriosonde 1217) and heart 
rate (electrocardiograph) were made every 3 min during the 
whole period of examination. In the results, however, only the 
values immediately before cooling are given. 
After this, a blood sample was taken for laboratory investi­
gation including plasma creatinine, glucose, serum glutamic 
oxaloacetic transaminase, serum glutamic pyruvic transaminase, 
hemoglobin, blood morphology, C l q binding assay, complement 
fractions C3, C4, factor B, ΑΝΑ-test. A urine analysis was 
performed, and body weight was recorded. The results of the 
C l q binding assay, the ΑΝΑ-test, and the determination of C3, 
C4, factor В will be delt with elsewhere. In the 8th week of the 
trial all patients answered without assistence of the physician 
a questionnaire about clinical symptoms and side-effects as 
compared to the before treatment situation. 
Analysis of Data 
For analysis of all data obtained by objective measurements 
(finger temperature, body weight, blood pressure, and heart rate) 
the cross-over design was used. To test whether this design was 
valid, values prior to each of the two treatments were compared 
with each other (Figure 1 : values at A and D versus values at В 
and C). To trace carry-over effects, values prior to any treat­
ment were compared with the 8 weeks placebo values, separately 
for the patients starting on alpha-blockade and on alpha-beta-
blockade (Figure 1: values at A versus at B, at С versus at D). 
To trace time-effects the same comparison was performed for the 
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TABLE 1 
Mean finger temperature 12 min after finger cooling prior to treatment 
1st period prior to alpha-blockade (А, и = 16) 20.3 ± 1.8 0 C 
3rd period prior to alpha + beta-blockade (Β, η = 16) 20.6 ± 2.2 „ 
1st period prior to alpha + beta-blockade (С, и = 15) 20.5 ± 1.5 „ 
3rd period prior to alpha-blockade (D, и =15) 19.3 ± 1.5 „ 
1st period prior to alpha- and 3rd period prior 
to alpha-blockade ( A + D, и = 31) 19.8+1.7 „ 
3rd period prior to alpha + beta-blockade and 1st period 
prior to alpha + beta-blockade (В + C, и = 31) 20.4 ± 1.9 „ 
A, B, C, and D refer to points in Figure 1. 
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whole group (Figure 1: values at A and С versus at В and D). 
Other tests on carry-over effects were not applied, because of 
the small number of patients and the small power of these kinds 
of tests [11, 12]. 
The results of 4 and 8 weeks alpha-blockade were compared 
with the values prior t o alpha-blockade and with each other 
(31 patients). The same procedure was performed on alpha + 
beta-blocker effects were analysed using the difference between 
posttreatment value and pretreatment value as parameter for 
comparison (32 patients). 
For analysis of clinical symptoms and side-effects a parallel 
group study of the first 8 weeks of the trial was performed. 
Decrease of complaints and appearance of side-effects after 8 
weeks alpha-blockade (16 patients) were compared with the 
effects after 8 weeks alpha + beta-blockade (15 patients). 
For statistical analysis of the cross-over design Wilcoxon's 
test for paired data was used (two-seded, except for the results 
after 4 and 8 weeks treatment in comparison with the values 
prior to the same treatment, that were tested one-sided). For 
analysis of the parallel group study the Fisher's exact test for 
2X 2-table was used. We calculated 95% confidence intervals for 
the probabilities of decrease of complaints and appearance of 
side-effects. P-values of 0.05 or less were considered significant. 
Results are presented as mean ± standard deviation (S.D.). 
5.3. RESULTS 
Tests for the Validity of the Cross-over Design 
(Objective Measurement) 
No significant differences were found between the values prior 
to each of the two treatments (Figure 1: values at A and D versus 
values at В and C), except for the mean fìnger temperature 12 
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min after finger cooling (Table 1) that was slightly lower prior 
to alpha-blockade than prior to alpha+ beta-blockade (19.8± 1.7 
"C versus 20.4 ± 1.9 0 C, p< 0.05). This difference was caused by 
a difference between the 8 weeks placebo values (D) and the 
values prior to any treatment (C) in the group starting on alpha + 
beta-blockade (Figure 1 : difference between values at D and values 
at C, mean decrease of —1.1 ± 2.8 "C, p< 0.01). No other signifi­
cant differences were found between 8 weeks placebo values and 
values prior to any treatment (Figure 1: values at A versus B, 
at С versus D, values at A and С versus at В and D). Despite the 
established slight difference in one parameter, the cross-over 
design was considered valid, as will be discussed later. Moreover, 
further analysis of quantitative data have been performed using 
a procedure that is not influenced by differences in pretreatment 
values. 
Quantitative Effects of Alpha-blockade 
The recovery of finger temperature 12 min after finger cooling 
significantly increased after 4 and after 8 weeks alpha-blockade 
(Table 2). The 4 weeks value was significantly lower than the 
8 weeks value (23.7 versus 24.5 "С, ρ < 0.05). Also immediately 
after finger cooling (0 min) the alpha-blocker had a significant 
effect on finger temperature after 8 weeks treatment. This therapy 
did not influence blood pressure or heart rate. However, body 
weight significantly increased after 8 weeks treatment with a mean 
value of 2 kg. This was accompanied by obvious edema in 6 
patients. Laboratory investigation and urine analysis did not reveal 
relevant differences as compared to the before-treatment situation. 
Quantitative Effects of Alpha+ beta-blockade 
Also on alpha + beta-blockade there was a significant increase 
of finger temperature 12 min after finger cooling (Table 2). 
Again the 4 weeks value was significantly lower than the 8 weeks 
•ν) 
о 
TABLE 2 
Influence of 
Finger temperature ( C) 
before cooling 
Immediately after cooling 
12 min after cooling 
Systolic pressure (mm Hg) 
Diastolic pressure (mm Hg) 
Heart rate (beats/min) 
Body weight (kg) 
alpha-blockade and alpha + beta-blockade on 
(mean values ± S.D.) 
Alpha-blockade 
Before 
treatment 
м = 3 1 
27.2 ± 3 . 6 
17.9 ± 1.0 
19.811.7 
127 ± 1 4 
85 ± 1 0 
75 ± 1 1 
68.7 ± 11.5 
4 weeks 
treatment 
»i = 31 
28.1 ± 3.0 
18.5 ± 1 . 2 
23.7 ± з.г**'' 
128 ± 1 3 
85 ± 1 0 
77 ± 1 1 
68.9 ±11.3 
8 weeks 
treatment 
и = 31 
28.6 ± 3.2 
18.8 ± 1.1**" 
1
 24.5 ± 3 . 2 * * * 
125 ± 1 3 
83 ± 9 
77 ± 1 5 
70.7 ± 10.9* 
the objectively measured variables 
Alpha + beta-blockade 
Before 
treatment 
и = 31 
27.4 ± 3.7 
* 18.3 ± 1.0 
• 20.4 ± 1.9 
127 ± 1 1 
85 ± 9 
76 ± 1 0 
69.0 ± 11.7 
4 weeks 
treatment 
и = 31 
28.6 ± 3.5 
18.5 ± 1.8 
8 weeks 
treatment 
n = 31 
29.2 ± 3 . 5 * 
19.4 ± 1.9** 
24.1 + 4.8*** 25.3 ± 4 . 3 * * * 
126 ± 16 
84 ± 1 2 
70 ± 1 2 * * 
69.5 ±11.5 
123 ± 1 5 
81 ± 1 1 
7 0 + 1 2 * * * 
68.5 ±11.0 
Wilcoxon's test for paired data is used to compare 4 and 8 weeks values with the values prior to the same treatment. 
* ρ < 0.05 
** ρ < 0.01 
*** ρ < 0.001 
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value (24.1 versus 25.3 "C; p < 0 . 0 1 ) . This therapy did not 
influence blood pressure or body weight. However, heart rate 
significantly fell. Laboratory investigation of blood and urine did 
not reveal relevant differences as compared to the values before 
alpha + beta-blockade. 
Quantitative Effects of Alpha-blockade Versus 
Alpha+ beta-blockade 
Using the difference between posttreatment value and pre-treat-
ment value as parameter for comparison between alpha-blocker 
and alpha + beta-blocker effects (Table 3), the influence of the 
therapies on heart rate and on body weight were significantly 
different: on alpha + beta-blockade heart rate fell, whereas body 
weight did not rise. However, the influences of the therapies 
on finger temperature were not significantly different. 
Clinical Symptoms and Side-effects 
Table 4 gives the number of patients who experienced improve-
ment of symptoms in the first 8 weeks of the trial. The 95% 
confidence interval, reflecting the chance of decrease of com-
plaints, was between 35 and 85% for the general complaints on 
alpha-blockade, between 21 and 73% on alpha + beta-blockade. 
The incidence of side effects is given in Table 5, with 95% confi-
dence intervak. The major side effects of the two medications 
were nasal congestion, disturbed ejaculation and potence, dry 
mouth, tiredness, exercise-induced and orthostatic dizziness. 
Other possible side-effects such as itch, loss of appetite, obsti-
pation, diarrhée, muscle weakness, gastric pain, nausea, vomiting, 
blurred vision, disturbed concentration appeared to be unim-
portant and have, therefore, not been presented. None of the 
patients experienced a collaps. No significant differences between 
the scores for alpha-blockade and alpha + beta-blockade were 
found. 
TABLE 3 
Increase or decrease of objectively measured variables after alpha-blockade (posttreatment minus pretreatment 
values) compared with the increase or decrease after alpha + beta-blockade. 
4 weeks treatment 8 weeks treatment 
α-blockade ρ a + J3- α-blockade ρ a + /3-
blockade blockade 
и = 31 и = 31 и = 31 « = 31 
Finger Min after 
temperature fìnger 
( С) cooling 
Before cooling + 0.9 ± 2.9 NS + 1 . 2 ± 3 . 8 + 1 . 4 ± 3 . 5 NS + 1.8 ± 4.5 
Immediately after cooling + 0 . 6 ± 1 . 5 NS + 0 . 2 ± 1 . 6 + 0 . 9 ± 1 . 2 NS + 1.1 ± 1.8 
12 min after cooling + 3.9 ± 3.0 NS + 3.7 ± 4.5 + 4.7 ± 3.2 NS + 4.9 ± 4.4 
Systolic pressure (mm Hg) + 1 ± 10 NS - 1 ± 17 - 2 ± 15 NS - 4 ± 16 
Diastolic pressure (mm Hg) 0 ±7 NS - 1 ± 11 - 2 ± 10 NS + 4 ± 10 
Heart rate (beats/min) + 2 ± 10 ρ < 0.05 - 6 ± 1 0 + 2 ± 1 0 p< 0.05 - 6 ± 9 
Body weight (kg) + 0 . 2 ± 1 . 1 NS + 0.5 ± 1.6 + 2.0 ± 2.0 ρ < 0.05 - 0.5 ± 2.0 
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TABLE 4 
Number of patients experiencing a decrease (yes) or no decrease (no) of 
complaints after the first 8 weeks of treatment. 
Decrease of 
complaints 
General 
Coldness 
Pain 
White color 
Blue color 
Lesions 
Duration of 
attacks 
alpha i-blocker 
и = 16 
yes 
10 
10 
9 
7 
7 
5 
7 
no 
6 
6 
7 
9 
9 
11 
9 
95% confidence 
interval 
35-85 
35-85 
30-80 
2 0 - 7 0 
2 0 - 7 0 
11-59 
20-70 
(%) 
alpha + beta-blocker 
n = 15 
yes 
7 
4 
5 
6 
4 
4 
8 
no 
8 
11 
10 
9 
11 
11 
7 
95% confidence 
interval (%) 
2 1 - 7 3 
8-55 
12-62 
16-68 
8-55 
8-55 
27-79 
5.4. DISCUSSION 
The design of our study was very much determined by a number 
of limitations. First of all, the trial had to take place in the colder 
part of the year, because of the seasonal character of Raynaud's 
syndrome and, in order to avoid bias due to the type of winter, 
had to be accomplished in one winter. Also, the withdrawal of 
previous drugs had to take place already in the colder season. 
For the latter, the months of September and October were chosen. 
For data from objective measurements a cross-over design 
was chosen, because of the advantage of paired comparisons 
between alpha-blocker and alpha + beta-blocker effects. In using 
a cross-over design one has to deal with the potential biases of 
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TABLE 5 
The prevalence of side-effects after the first 8 weeks treatment 
Side effects 
Nasal congestion 
Alcohol intolerance 
Urine incontinence 
Disturbed ejaculation* 
Disturbed potence* 
Depression 
Dry mouth 
Tiredness 
Palpitations 
Dizziness at rest 
Dizziness with exercise 
Orthostatic dizziness 
Sleepiness 
Alpha-blocker 
и = 
yes 
10 
2 
5 
4 
4 
4 
8 
9 
5 
4 
8 
8 
5 
16 
no 
6 
12 
11 
2 
2 
12 
8 
7 
11 
12 
8 
8 
10 
95% confidence 
interval 
35-85 
2 - 4 3 
11-59 
2 2 - 9 6 
22-96 
7 - 5 2 
25-75 
3 0 - 8 0 
11-59 
7 - 5 2 
25-75 
25-75 
12-62 
(%) 
alpha + beta-blocker 
η = 
yes 
10 
2 
5 
2 
2 
6 
11 
11 
2 
5 
12 
10 
9 
15 
no 
5 
13 
10 
2 
2 
9 
4 
4 
13 
10 
3 
5 
6 
95% confidence 
interval (%) 
38-88 
4 - 7 1 
12-62 
7 - 9 3 
7 - 9 3 
16-68 
4 5 - 9 2 
4 5 - 9 2 
2 - 4 0 
12-62 
52-96 
3 8 - 8 8 
3 2 - 8 4 
Figures relate to the number of patients showing the particular side effects 
or not after 8 weeks treatment. Some questions were not answered by all 
patients. 
* Only for male patients. 
carry-over effects and time effects [11]. However, adrenergic 
receptor blocking drugs are not curative and rather short-acting. 
After withdrawal of beta-blockers for 2—3 days a rebound phe­
nomenon may even occur [13], but then the pretreatment situa­
tion returns. Therefore, no carry-over effects can be expected. 
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Secondly, the choice in the season and the equilibration time at 
24 0 C before each experiment should minimize any time effects. 
Nevertheless, we judged it a matter of course to test for these 
effects and, indeed, found no difference between values prior 
to any treatment and 8 weeks placebo values, except for the 
finger temperatures 12 min after finger cooling in the patients 
starting on alpha + beta-blockade. However, since this difference 
was only small and since the values after the placebo period were 
even lower than those prior to any therapy, we consider the 
difference to have risen rather by chance than due to a carry-
over effect. The finding does not invalidate the over-all con-
clusions of this report, because effects of the two drug regimens 
are compared on the base of difference between posttreatment 
values and values prior to the same treatment and not on absolute 
values. 
For analysis of clinical symptoms and side-effects a cross-over 
design is very likely to be biased by psychological carry-over 
effects [14]. Therefore, these parameters have been analysed as 
a parallel group study of the first 8 weeks of the trial. 
Finger skin temperature is highly related to total finger blood 
flow [10] and can therefore be applied to measure the disap-
pearance of a cold-induced vasoconstriction. A standard finger 
cooling test serves as a model for a Raynaud's attack. We previ-
ously demonstrated that the recovery of finger temperature 
after a standard finger cooling test is reproducible if air tempera-
ture and smoking are controlled [9, 10] and that it is significantly 
lower in patients with Raynaud's syndrome than in normal sub-
jects [1]. This was considered as evidence for the validity of this 
method. 
The present study clearly indicates that chronic alpha-blockade 
improves the recovery of fìnger temperature after cooling. The 
significantly higher 12 min temperature at 8 weeks than at 4 
weeks probably is more due to doubling of the dose after 4 
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weeks than to the longer period of treatment. The improvement 
of finger temperature recovery is in accordance with the decrease 
of complaints as registered by the questionnaire. However, with 
the given doses the effect was not seen in all patients. The cause 
for a poor response in some patients is unclear and is object 
of further study in our clinic. 
The influence of the drug on blood pressure and heart rate 
in our resting, sitting, normotensive patients was negligible. 
However, body weight after 8 weeks of treatment increased, pre-
sumably due to fluid retention. This effect has been reported of 
vasodilating antihypertensive drugs. It is generally ascribed to 
stimulation of the renin-angiotensin-aldosterone system via arterial 
hypotension [15]. This mechanism seems unlikely in our patients 
because of absence of hypotension. However, stimulation of the 
above system via indirect beta-stimulation seems a more plausible 
explanation. In fact alpha-blocker side effects have been con-
sidered due to indirect beta-stimulation [7J. Side effects generally 
were mild and never, except in one case, urged patients to leave 
the trial. Nevertheless, some side effects were very common, e.g. 
nasal congestion, disturbed ejaculation and potence, dry mouth, 
tiredness, dizziness. 
The benificial effect of the alpha-blocker phenoxybenzamine 
was not reduced by the addition of the non-selective, long acting 
beta-blocker Sotalol (f Vi 17 hours) [16]. This is in accordance 
with the effects from our single dose study [1] and should 
encourage studies on treatment of beta-blocker induced peripheral 
coldness [17, 18] with alpha-blockers. Furthermore, it prevented 
the increase of body weight, caused by the alpha-blocker alone. 
This supports the above concept that the weight gain is caused 
by stimulation of renal beta-receptors. The beta-blocker, there-
fore, is of practical use in preventing fluid retention due to alpha-
blockade. 
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The addition of a beta-blocker to the alpha-blocker resulted 
in a lower heart rate, which supports the concept that another 
alpha-blocker side-effect, tachycardia, may be counteracted by 
beta-blockade. However, tachycardia was not observed in our 
trial during alpha-blockade alone. The addition of the beta-blocker 
to the alpha-blocker did not influence blood pressure. It is 
remarkable, that two potentially hypotensive drugs in these 
normo tensive patients did not lower blood pressure. 
No significant differences between the effects of the two 
therapies could be demonstrated, although a decrease of com­
plaints was noticed in more patients during alpha-blockade than 
during alpha + beta blockade. However, we must admit that it 
is hard to demonstrate small differences in this material, because 
of the rather small number of subjects. 
Finally, it may be concluded that alpha-blockade is, both 
subjectively and objectively, effective in the majority of patients 
with Raynaud's syndrome. The benificial effect improves with 
increase of the dose. Additional beta-blockade does not attenuate 
the benificial effect. Additional beta-blockade counteracts the 
alpha-blocker side effect fluid retention, reduces the heart rate, 
and may, therefore, also counteract alpha-blocker induced tachy­
cardia, and does not cause hypotension. 
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CHAPTER 6 
THERAPEUTIC EFFICACY OF 
ALPHA-ADRENOCEPTER BLOCKADE IN 
PRIMARY AND SECONDARY RAYNAUD'S 
SYNDROME 
Abstract. Twenty patients with primary and 11 with secondary Raynaud's 
syndrome were treated with the alpha-adrenoceptor blocker phenoxybenza-
mine (10—20 mg daily). In the secondary group mean age and mean duration 
of symptoms as well as presence of positive ANA and positive Clq binding 
test were significantly higher than in the primary group. In both groups a 
beneficial effect of the medication on finger temperature 12 min after finger 
cooling and on clinical symptoms was established. Secondary Raynaud's 
syndrome reacted at least as well as the primary syndrome. 
6 .1 . INTRODUCTION 
Patients with Raynaud's phenomenon with associated auto-
immune disease are classified as having secondary Raynaud's 
syndrome, and those without auto-immune phenomena as primary 
Raynaud's syndrome. Primary Raynaud's syndrome is considered 
as a purely vasospastic disease, secondary as both a vasospastic 
and obstructive disease [1]. Therefore, one might expect less 
therapeutic susceptibility to alpha-adrenergic receptor blockers 
in the secondary than in the primary syndrome. However, this 
has never been studied. In the present report patients with primary 
and with secondary Raynaud's syndrome are compared as to the 
effects of alpha-blockade on the recovery of finger temperature 
after cooling and on clinical symptoms. The paper presents the data 
of the first part of a double blind cross-over study of the effects 
of alpha-blockade and alpha + beta-blockade in Raynaud's syn-
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drome. Comparison of the two treatments is reported elsewhere 
[21. 
6.2. MATERIAL A N D METHODS 
Of the patients with Raynaud's syndrome, who were available at 
our outpatient clinic, 32 gave their informed consent to the 
trial. Thirty one patients completed the trial; one dropped out 
because of nausea. Diagnoses had been established by the con-
ventional criteria [3]. Raynaud's disease (primary Raynaud's 
syndrome) had been diagnosed in twenty patients, Raynaud's 
syndrome with connective tissue disease (secondary Raynaud's 
syndrome) in eleven (five with systemic sclerosis, three with 
reumatoid arthritis, two with CREST* syndrome, one with 
polymyositis). The duration of the syndrome at the time of entry 
into the study varied from 2 to 44 years (average 7.7 years). There 
were twenty-one women and ten men. Patients stopped any drug 
therapy concerning Raynaud's syndrome 8 weeks before entering 
the study. They were all nonsmokers, or had stopped smoking 
since at least 12 months. 
Design of the Study 
The patients were divided in two groups by block randomisation. 
One group (16 patients) received phenoxybenzamine during 8 
weeks. In the first 4 weeks the dose was 5 mg twice daily, in the 
second 4 week period 10 mg twice daily. The other group (15 
patients) received the same dose of phenoxybenzamine, however, 
in combination with the beta-blocker Sotalol, 20 mg twice daily 
in the first 4 weeks and subsequently 40 mg twice daily. The 
* CREST = Calcinosis, Raynaud, Esophageal hypomotility, Scleroderma, 
Teleangiectasia. 
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combination with the beta-blocker was given in order to study 
the possibility of reducing the side-effects of alpha-blockade. 
The comparison of the effects of these two regimens is reported 
elsewhere 12]. Concerning the therapeutic effect no significant 
difference appeared between the two groups. For the purpose 
of this study both groups are taken together for a comparison 
between patients with primary and patients with secondary 
Raynaud's syndrome. 
Before, after 4 and after 8 weeks treatment all patients were 
examined at our outpatient clinic. The examination contained 
the following finger cooling test. The patient was seated quietly 
in a room of 24 0 C (in order to prevent a physiological vasocon­
striction) [4], at a humidity of 40%. After 15 min the temperature 
of the volar surface of the top of the third finger was determined 
by an electronic thermometer. Then, the patient's hands were 
placed in well-fitting plastic gloves and immersed in water of 16 0 C 
to just beyond the metacarpophalangeal joints during 5 min. The 
patient gently moved his hands to intensify the cooling. After 
taking off the gloves, finger temperature was measured as before 
each min for 12 min. Finger temperature after 12 min was used 
as a measure for temperature recovery, because in most healthy 
subjects at this moment a complete recovery has been reached [5]. 
At the end of the examination of blood sample was taken for the 
C l q binding assay [6], complement fractions C3, C4, factor B, 
and the ANA-test [7]. The level of C l q binding activity is expressed 
as the number of standard deviations difference from the mean of 
10 normal human sera. In the results those patients are called 
Clq-positive, respectively ΑΝΑ-positive, who at one or more 
visits had a C l q binding activity of more than 5 standard devia­
tions above the normal mean, or a positive ΑΝΑ-test. In the 8th 
week of the study all patients answered without assistence of the 
physician a questionnaire about clinical symptoms as compared 
to the before-treatment situation. 
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Analysis of Data 
The patients were divided into groups with primary and secon-
dary Raynaud's syndrome. Although the addition of the beta-
blocker did not influence the alpha-blocker effects on the fìnger 
cooling test [2], the primary and secondary groups were tested 
for equal distribution of patients using the additonal beta-blocker 
together with the alpha-blocker. These two groups were also tested 
for difference in distribution of sex, age, duration of symptoms, 
positive ANA and positive C lq binding test. Finger temperatures 
before and after fìnger cooling after 4 and after 8 weeks of alpha-
blockade were compared with the corresponding values prior to 
alpha-blockade for each of the two groups. Then, the two groups 
were tested for differences in fìnger temperatures. Finally they 
were tested for difference in decrease of complaints after 8 weeks 
alpha-blockade. 
For statistical analysis we used the Mann—Whitney test for 
two sample comparison, the one-sided Wilcoxon-test for paired 
data and the chi-square test for binary data. 
6.3. RESULTS 
Sex distribution and the number of patients using alpha + beta-
blockade in stead of alpha-blockade were not significantly differ-
ent in both groups. Nine patients with primary Raynaud's syn-
drome and 7 with secondary Raynaud's syndrome used only an 
alpha-blocker. However, mean age and mean duration of symp-
toms were significantly lower in the primary group than in the 
secondary group (Table 1). As could be expected, the numbers 
of ΑΝΑ-positive and Clq-positive patients were significantly 
higher in the secondary group. The levels of the complement 
fractions C3, C4 and factor В generally were normal, without 
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TABLE 1 
Clinical characteristics in 31 patients with Raynaud's syndrome 
Number of men 
Number of women 
Mean age (years) ± SD 
Mean presence of symptoms 
(years) ± SD 
Number of ANA-positives 
Number of AN A-negatives 
Number of Clq-positives 
Number of Clq-negatives 
Primary Raynaud 
и = 20 
7 
13 
41.0110.9 
4.3 ± 2.8 
8 
12 
5 
15 
Secondary Raynaud 
n = l l 
3 
8 
54.2 ± 15.7* 
13.8 ± 1 1 . 9 * 
10* 
1 
8* 
3 
S.D. = standard deviation. 
* Different at'significant level (p < 0.05). 
differences between the groups and will, therefore, not be 
reported in detail. 
In both groups alpha-blockade significantly improved finger 
temperature 12 min after cooling (Table 2). No significant differ­
ences in finger temperature between primary and secondary 
Raynaud's syndrome were found, except for the temperature 
12 min after fìnger cooling at 8 weeks of alpha-blockade, that 
was significantly higher in the secondary group (p < 0.01). 
Table 3 enumerates the patients who experienced a decrease 
of symptoms at 8 weeks of alpha-blockade. There seems to be a 
tendency to more subjective improvement in patients with the 
secondary syndrome, although this difference with the primary 
syndrome only reached statistical significance in two categories 
of complaints. 
TABLE 2 00 
Finger temperature after different periods of alpha-blockade in primary and in secondary Raynaud's syndrome in 
comparison with the values prior to alpha-blockade. 
Primary Raynaud Secondary Raynaud 
и = 20 и = 11 
0 weeks 4 weeks 8 weeks 0 weeks 4 weeks 8 weeks 
Finger 
temperature ( C) 
before fìnger 
cooling 28.3 ±3 .9 28.1 ± 3.8 29 .6+3 .2 26.8 ± 4.0 28.4 ± 3.0 30.5 ±1 .9** 
immediately 
aftercooling 17.8 ± 0.9 17.8+1.1 18 .7±1 .1 18.1 ± 0.8 18 .1±1.7 18.8+1-5 
12 min after 
cooling 20.3± 1.6 22.9± 4.3(*) 24 .0±4 .0** 20 .6±1.7 24 .4±4 .0** 26 .2+2 .3*** 
Finger temperatures are expressed as mean ± standard deviation. The one-sided Wilcoxon's test for paired data is 
used to compare differences between before and after treatment values. 
(*) 0.05 <p < 0.1 
* p < 0 . 0 5 & 
** ρ < 0.01 Ί 
*** ρ < 0.001 * 
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TABLES 
Decrease of complaints after 8 weeks alpha-blockade 
Complaints 
General 
Coldness 
Pain 
White color 
Blue color 
Lesions 
Duration attacks 
Primary Raynaud 
Decrease 
yes 
7 
7 
8 
7 
5 
5 
7 
no 
13 
13 
12 
13 
15 
15 
13 
95% con-
fìdence 
interval 
15-59* 
15-59 
19 -64 
15 -59 
9 - 4 9 
9 - 4 9 
15-59* 
Sec ondary Raynaud 
Decrease 
yes 
8 
7 
6 
6 
6 
4 
8 
no 
3 
4 
5 
5 
5 
7 
3 
95% con-
fidence 
interval 
3 9 - 9 4 
3 1 - 8 9 
2 3 - 8 3 
2 3 - 8 3 
2 3 - 8 3 
10-69 
3 9 - 9 4 
* Secondary versus primary different at a significant level (p < 0.05). 
6.4. DISCUSSION 
Finger temperature is approximately linearly related to finger 
blood flow [8] and can therefore be used as a measure for the 
degree of vasoconstriction. In both primary and secondary Ray-
naud's syndrome alpha-blockade improved clinical symptoms 
and finger temperature 12 min after finger cooling. Because of 
the both vasospastic and obstructive origin of secondary Raynaud's 
syndrome [1], one might expect that secondary Raynaud's syn-
drome is less susceptible to drug therapy than primary. However, 
in our study alpha-blockade improved finger temperatures and 
clinical symptoms in secondary Raynaud's syndrome at least as 
well as in primary. The higher finger temperature 12 min after 
fìnger cooling at 8 weeks alpha-blockade and the tendency to 
more subjective improvement may even indicate that secondary 
Raynaud's syndrome is somewhat more susceptible than primary. 
We have no explanation for this unexpected finding. However, 
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because of the low level of significance the differences may have 
arisen by chance as well. 
The favourable effect of alpha-blockade in both primary and 
secondary Raynaud's syndrome suggests that disproportionate 
alpha-receptor mediated vasoconstriction is responsible for the 
two forms of Raynaud's phenomenon. Vanhoutte and Janssens 
[9] hypothesized from their in vitro studies with isolated cutane­
ous vessels, that Raynaud's phenomenon may be caused by an 
imbalance between vascular alpha- and beta-receptors due to a 
relative lack of beta-receptor sensitivity. It is tempting to assume 
that this lack of beta-receptor sensitivity is caused by auto-anti­
bodies against beta-receptors as were recently demonstrated in 
another autonomic abnormality [10]. The presence of these anti­
bodies in secondary Raynaud's syndrome, manifesting with 
auto-immune disease, is conceivable. The possibility that they are 
also present in our primary Raynaud-patients is supported by the 
high incidence of positive ANA and positive C l q binding tests 
in this group. Raynaud's phenomenon in the secondary syndrome 
may preceed the manifestation of auto-immune disease for many 
years [11]. This is consistent with the higher age and longer duration 
of symptoms in these patients in our study, and furthermore it 
suggests that the two conditions indeed have a similar patho­
genesis. 
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SAMENVATING 
Hoofdstuk 1 van dit proefschrift bevat een beknopt historisch 
overzicht over het syndroom van Raynaud. De vele in het ver-
leden toegepaste therapieën passeren daarbij de revue. Noch 
van chirurgische ingrepen als sympathectomie, noch van de meeste 
medicamenteuze behandelingen is ooit meer dan een hoogstens 
tijdelijk effect bewezen. De laatste decennia zijn echter regel-
matig gunstige effecten waargenomen van stoffen die invloed 
hebben op de adrenerge receptoren. Deze waarnemingen zijn voor 
ons aanleiding geworden tot de hieronder weergegeven bespiege-
lingen en vraagstellingen. 
Volgens de theorie van Ahlquist bevatten de huidvaten voor-
namelijk receptoren van het alpha-type. Activering van deze 
receptoren resulteert in vasoconstrictie. Toen dan ook de alpha-
blokkeerder phenoxybenzamine ter beschikking kwam, werd dit 
middel van meet af aan bij Raynaud-patiënten toegepast. Daarbij 
werden gunstige resultaten bereikt. Aangetekend moet echter 
worden dat de werkzaamheid nooit echt in een gecontroleerde 
studie is bewezen. Het is dus niet geheel uit te sluiten dat het 
effect van phenoxybenzamine slechts een placebo-effect is. In 
onze studie hebben wij daarom op de eerste plaats getracht over de 
eventuele werkzaamheid van alpha-blokkeerders bij het syndroom 
van Raynaud grotere zekerheid te krijgen. 
Van beta-blokkerende middelen is bekend dat zij bij gezonden 
Raynaud-achtige verschijnselen kunnen veroorzaken. Dit heeft 
aanleiding gegeven tot het toedienen van beta-stimulators aan 
patiënten met het syndroom van Raynaud. Inderdaad zijn van b.v. 
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terbutaline gunstige effecten waargenomen; systematisch en ge-
controleerd onderzoek is echter op dit punt nooit gedaan. Een 
tweede doel van onze studie was dan ook vast te stellen of beta-
stimulering bij het syndroom van Raynaud werkelijk van voordeel 
is. 
In het verleden zijn bij de behandeling van het syndroom 
van Raynaud de alpha-blokkerende middelen nooit erg populair 
geworden. Dit valt toe te schrijven aan hun bijwerkingen, met 
name de tachycardie en de orthostatische hypotensie. Een recente 
theorie verklaart deze bijwerkingen als het gevolg van indirecte 
beta-stimulering. 
Het leek dus de moeite waard om bij Raynaud-patiënten na te 
gaan of de ongewenste neven-effecten van alpha-blokkeerders 
zouden kunnen worden voorkomen door toevoeging van een 
beta-blokkeerder. Tegelijkertijd hebben we daarbij onderzocht of 
door de toevoeging van een beta-blokkeerder geen afbreuk zou 
worden gedaan aan het eventueel gunstige effect van de alpha-
blokkeerder. 
Enigszins los van de bovenstaande overwegingen hebben wij ons 
tenslotte nog afgevraagd of er een verschil in behandelbaarheid 
zou bestaan tussen primaire en secundaire vormen van het syn-
droom van Raynaud. De primaire vorm van het syndroom van 
Raynaud immers wordt beschouwd als een zuiver vasospastische 
aandoening. Bij de secundaire vormen zouden veelal ook anato-
mische factoren een pathogenetische rol spelen. Het is dus niet 
uit te sluiten dat de secundaire vorm van het syndroom minder 
goed toegankelijk is voor medicamenteuze behandeling dan de 
primaire. 
In hoofdstuk 2 wordt aan de hand van literatuurgegevens 
beargumenteerd, dat de temperatuur van de huid van de vinger 
een goede parameter is voor de doorbloeding van die vinger. 
De veneuze occlusie-plethysmographie schiet in dit opzicht bij 
lagere huidtemperaturen veelal tekort. Uit de Uteratuur blijkt, 
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dat een lage omgevingstemperatuur de vingerdoorbloeding negatief 
beïnvloedt. Ook het roken van een sigaret heeft blijkens de litera-
tuur een, overigens snel voorbijgaande, vermindering van de huid-
doorbloeding tot gevolg. Tenslotte wordt vermeld, hoe in de litera-
tuur het herstel van de vingertemperatuur na blootstelling van de 
hand een koude wordt beschouwd ab maatstaf voor het effect 
van geneesmiddelen bij het syndroom van Raynaud. Ook in ons 
onderzoek heeft een dergelijke koude-provocatie-test een centrale 
rol gespeeld bij de beantwoording van de vraagstellingen. 
In hoofdstuk 3 wordt verslag gedaan van eigen experimenten 
rond het herstel van de vingertemperatuur na blootstelling van de 
hand aan koude, zoals die werden gedaan bij normale proef-
personen. 
Na een gestandaardiseerde afkoeling bleek het herstel van de 
vingertemperatuur een vlot en intra-individueel goed reproduceer-
baar verloop te hebben. Deze goede reproduceerbaarheid vormde 
voor ons een ondersteuning voor de toepasbaarheid van dit type 
proeven bij de beoordeling van de effectiviteit van geneesmiddelen 
bij het syndroom van Raynaud. 
De experimenten ter beoordeling van de reproduceerbaarheid 
van het vingertemperatuurherstel werden verricht bij een kamer-
temperatuur van 24 0 C. Dezelfde proefpersonen ondergingen de 
testen nog voor een derde maal, nu echter bij een kamertempera-
tuur van 20 0 C. Thans was in het algemeen van enig temperatuur-
herstel in het geheel geen sprake. Blijkbaar dient dit type experi-
menten bij voldoende hoge omgevingstemperatuur te worden 
uitgevoerd. 
Tenslotte bleek ook het roken van sigaretten het temperatuur-
herstel op onvermoede wijze te beihvloeden. Zoals reeds vermeld 
doet het roken van een sigaret de vingertemperatuur dalen. Een 
tiental minuten na het beëindigen van de sigaret is de vinger-
temperatuur alweer normaal. Het herstel van de vingertemperatuur 
na koude-expositie is dan echter nog sterk gestoord. Deze stoornis 
is vaak zelfs 24 uur later nog steeds aanwezig. 
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Bij onze Raynaud-patiënten hebben wij daarom het vinger-
temperatuurherstel na koude-expositie steeds onderzocht bij 
de vrij hoge kamertemperatuur van 24 0 C. Raynaud-patienten, 
die rookten, werden niet in het onderzoek betrokken. 
Hoofdstuk 4 beschrijft een pilot-studie naar de effectiviteit van 
diverse adrenoreceptor-beihvloedende geneesmiddelen en combi-
naties daarvan bij twaalf Raynaud-patiënten. De geneesmiddelen 
werden dubbelblind toegediend in éénmalige doses. Na toediening 
van de betai-stimulator prenalterol en van de beta2 -stimulator 
terbutaline was het vingertemperatuurherstel na koude-expositie 
geheel vergelijkbaar met het herstel na placebo, namelijk praktisch 
nihil. Na de niet-specifieke beta-stimulator orciprenaline was er 
een marginale verbetering. De alpha-blokkeerder phenoxybenza-
mine veroorzaakte na eenmalig toediening een aanzienlijke ver-
betering van het temperatuurherstel. Deze verbetering werd noch 
versterkt noch verzwakt door toevoeging van hetzij prenalterol, 
hetzij terbutaline of propranolol aan de phenoxybenzamine-
medicatie. 
Geconcludeerd werd, dat beta-stimulering bij het syndroom 
van Raynaud weinig voordelen lijkt te bieden. Besloten werd om 
het althans na éénmalige dosering werkzame phenoxybenzamine, 
en ook de combinatie daarvan met propranolol, verder te be-
proeven in een langduriger behandelingssituatie. 
In hoofdstuk 5 wordt een cross-over trial beschreven, uitge-
voerd bij 32 Raynaud-patiënten. Daarin werden de effecten 
van een acht weken durende therapie met phenoxybenzamine 
alléén vergeleken met de effecten van een even lang durende 
behandeling met de combinatie phenoxybenzamine plus Sotalol. 
De medicaties werden dubbelblind toegediend. 
Ook op de langere termijn bleek de alpha-blokkeerder phenoxy-
benzamine gunstig werkzaam bij het syndroom van Raynaud. 
Niet alleen het vingertemperatuurherstel na koude-expositie 
verbeterde erdoor, maar ook het klachtenpatroon. 
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Deze gunstige effecten van het phenoxybenzamine bleven 
bij toevoeging van sotalol geheel onaangetast. Tijdens Sotalol plus 
phenoxybenzamine lag echter de hartfrequentie op een duidelijk 
lager niveau. Bovendien bleef tijdens de combinatie-therapie de 
vochtretentie, die tijdens phenoxybenzamine alléén optrad en die 
geduid kan worden als gevolg van indirecte beta-stimulering, 
achterwege. 
In hoofdstuk 6 werd tenslotte ingegaan op de vraag naar een 
eventueel verschil tussen primaire en secundaire vormen van het 
syndroom van Raynaud wat betreft toegankelijkheid voor medica-
menteuze behandeling. De veronderstelling was dat de secundaire, 
deels op anatomische afwijkingen berustende vormen wellicht min-
der goed zouden reageren op therapie dan de primaire, zuiver 
vasospastische vormen. Althans ten aanzien van behandeling met 
phenoxybenzamine bleek deze veronderstelling niet op te gaan: 
onze patiënten met een secundair Raynaud-lijden reageerden op 
de alpha-blokkeerder minstens even goed als de patiënten met 
primaire Raynaud-syndromen. 
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STELLINGEN 
behorende bij: T. J. M. Cleophas, Adrenergic Receptor Agonists 
and Antagonists in Raynaud's Syndrome, 1982. 
1. Bij het syndroom van Raynaud dient behandeling met een 
alfa-adrenergische blokkeerder overwogen te worden. 
— Dit proefschrift. 
2. Door aan een alfa-blokkerende behandeling bij een patient met 
het syndroom van Raynaud een beta-blokkerend middel toe 
te voegen wordt de door alfa-blokkering veroorzaakte vocht-
retentie voorkomen, terwijl er geen hypotensie ontstaat en 
het therapeutische effect niet wordt verminderd. 
— Dit proefschrift. 
3. Het secundaire syndroom van Raynaud is minstens even ge­
voelig voor behandeling met een alfa-blokkeerder als het 
primaire syndroom van Raynaud. 
— Dit proefschrift. 
4. Voor een gunstig effect van prostaglandin Ej bij het syndroom 
van Raynaud is het objectieve bewijs nog niet geleverd. 
— Cleophas, A. J. M., Fennis, J. F. M., and van 't Laar, Α.: 1981, Br. 
Med. J. 282,1476. 
5. Bij een niet traumatische lensluxatie dient de diagnose homo-
cystinurie overwogen te worden. 
— Drayer, J. I. M., Cleophas, A. J. M., Trijbels, J. M. F., Smals, A. G. M., 
and Kloppenborg, P. W. С: 1980, Neth.J. Med. 23, 89. 
6. Naproxen kan aanleiding geven tot een acute, ernstige, doch 
reversibele nierinsufficientie. 
— eigen waarneming 
7. Wanneer bij een zogenaamde cross-over studie met twee be­
handelingsperioden een verschil gevonden wordt in uitgangs-
situatie vóór beide behandelingsperioden en wanneer een 
carry-over effect onwaarschijnlijk is, verdient het aanbeveling 
bij de bewerking van de resultaten gebruik te maken van de 
verschillen tussen de waarden vóór en na behandeling. 
8. De opbrengst van een gastroscopie wordt meer bepaald door 
de vaardigheid van de gastroscopist dan door de duur van het 
onderzoek. 
9. Het gunstige effect van de beta-blokkeerder pindolol bij ortho-
statische hypotensie1 berust niet op zijn intrinsieke sym-
pathico mimetische activiteit, maar op blokkering van vascu-
laire betaj -receptoren en mag daarom ook van elke andere 
niet selectieve beta-blokkeerder verwacht worden. 
1
 Man in 't Veld, A. J. en Schalekamp, Μ. Α. D. Η.: 1981, Br. Med. 
J. 282, 929. 
10. Het gebruik van termen als coöperativiteit, therapietrouw en 
„compliance" suggereert dat de „schuld" van het falen van een 
therapie bij de patiënt ligt en leidt de aandacht af van het 
gebrek aan inlevingsvermogen, medegevoel en overtuigings-
kracht bij de arts. 
vrij naar F. J. Ingelfmger, M.D., Editor Emeritus, 1980, N. Engl. J. 
Med. 303, 1507. 
11. Bij bejaarden met diabetes mellitus is het voorschrijven van een 
dieet ab regel niet zinvol en vaak schadelijk. 
12. Het medische curriculum lijdt aan overcompleetheid en pseudo-
volledigheid. 
13. In zijn correspondentie over patiënten aan verwijzende collega's 
dient de specialist zich zowel te beperken tot ab zich toe te 
leggen op het geven van die informatie, waar de ontvanger 
van de brief behoefte aan heeft. 


